Triamcinolona para traquioniquia

Published in Dermatology

Journal Scan / Commentary · November 03, 2019

Intralesional Triamcinolone Matrix Injections for Treatment of Trachyonychia

Journal of the American Academy of Dermatology

TAKE-HOME MESSAGE

• Trachyonychia, which may be idiopathic or associated with lichen planus, psoriasis, and alopecia areata or universalis, is a therapeutic challenge. Topical calcipotriol/ betamethasone dipropionate, topical tazarotene, oral cyclosporine, and oral acitretin have shown limited efficacy.

• The authors recommend using triamcinolone acetonide (2.5 mg/mL in 1% lidocaine 0.1–0.2 mL) injections to the nail matrix every 4 to 8 weeks as a well-tolerated and effective treatment option that improves the nail texture and functionality in this condition.

– InYoung Kim, MD, PhD

Abstract 

Trachyonychia is a nail condition in which patients present with roughness and longitudinal ridging of the nail plates, often likened to sandpaper (opaque) or less commonly pearlescent nails  with longitudinally arranged pits (shiny). Trachyonychia is more often seen in children and most cases are idiopathic, but it is also associated with lichen planus, psoriasis, and alopecia  areata/universalis.1 Data on trachyonychia treatment in adults is limited to open label studies,  case series and case reports utilizing topical calcipotriol/betamethasone dipropionate, topical  tazarotene, oral cyclosporine, and oral acitretin, with limited efficacy or adverse effects. Trachyonychia is also often refractory to treatment and more likely to exhibit a chronic course in  adults. Thus, a safe and effective long term intervention is necessary.

Journal of the American Academy of Dermatology

Intralesional Triamcinolone Matrix Injections for Treatment of Trachyonychia

J Am Acad Dermatol 2019 Oct 04;[EPub Ahead of Print], MK Gupta, S Geizhals, SR Lipner 

Sent from my iPhone

Benjamin Hidalgo-Matlock
Skin Care Physicians of Costa Rica

Clinica Victoria en San Pedro: 4000-1054
Momentum Escazu: 2101-9574

Please excuse the shortness of this message, as it has been sent from
a mobile device.